CN Patent

CN119219716A — 新型GalNAc的靶向递送片段及其制备和应用

Assigned to Shanghai Weishen Pharmaceutical Co ltd · Expires 2024-12-31 · 1y expired

What this patent protects

本发明公开了一种如下式(I)所示的GalNAc递送分子，或其立体异构体，对映异构体，或其药学上可接受的盐，其中各基团的定义如说明书中所述。

USPTO Abstract

本发明公开了一种如下式(I)所示的GalNAc递送分子，或其立体异构体，对映异构体，或其药学上可接受的盐，其中各基团的定义如说明书中所述。

Drugs covered by this patent

eplontersen-sodium (EPLONTERSEN SODIUM)

Patent Metadata

Patent number: CN119219716A
Jurisdiction: CN
Classification: —
Expires: 2024-12-31
Drug substance claim: No
Drug product claim: No
Assignee: Shanghai Weishen Pharmaceutical Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.